IMAC Holdings, Inc. Stock price

Equities

BACK

US44967K3023

Healthcare Facilities & Services

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3.06 USD +0.33% Intraday chart for IMAC Holdings, Inc. +137.21% +38.46%
Sales 2023 * 6M Sales 2024 * 4.2M Capitalization 3.48M
Net income 2023 * -8M Net income 2024 * -2M EV / Sales 2023 * 0.58 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.83 x
P/E ratio 2023 *
-0.38 x
P/E ratio 2024 *
-1.28 x
Employees 85
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.44%
More Fundamentals * Assessed data
Dynamic Chart
Top Premarket Decliners MT
IPM Medical Group, Inc. acquired IMAC Regeneration Center in Arlington Heights, Illinois from IMAC Holdings, Inc.. CI
IMAC Holdings, Inc. Announces Executive Changes CI
The Regenerative Center, LLC entered into agreements to acquire Tangible and intangible assets of Kentucky operation of IMAC Holdings, Inc. for $0.07 million. CI
IMAC Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
IMAC Holdings Regains Compliance With Nasdaq Listing Rule MT
Labor Data, Inflation Woes Weigh on Exchange-Traded Funds, Equity Futures Premarket Friday MT
IMAC Holdings Implements 1-for-30 Reverse Stock Split MT
IMAC Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
IMAC Holdings, Inc. announced that it has received $4.3 million in funding from Theralink Technologies, Inc. and other investors CI
IMAC, Theralink Technologies Sign Merger Deal; IMAC Shares Jump MT
IMAC Holdings, Inc. Appoints Jeffrey Busch to Serve as Chairman CI
IMAC Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Theralink Technologies, Inc. entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. for $0.9 million in a reverse merger transaction. CI
Brain Scientific Inc. cancelled the acquisition of IMAC Holdings, Inc.. CI
More news
1 day+0.33%
1 week+137.21%
Current month+125.00%
1 month+112.50%
3 months+39.73%
6 months+70.00%
Current year+38.46%
More quotes
1 week
2.16
Extreme 2.16
3.27
1 month
1.22
Extreme 1.2176
3.94
Current year
1.22
Extreme 1.2176
3.94
1 year
1.22
Extreme 1.2176
10.62
3 years
1.22
Extreme 1.2176
82.50
5 years
1.22
Extreme 1.2176
175.50
10 years
1.22
Extreme 1.2176
216.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 15-02-28
Founder 50 00-07-31
Director of Finance/CFO 55 17-10-31
Members of the board TitleAgeSince
Director/Board Member 64 20-10-20
Director/Board Member 71 20-10-20
Chief Executive Officer 46 15-02-28
More insiders
Date Price Change Volume
24-03-28 3.06 +0.33% 369,371
24-03-27 3.05 +27.08% 1,371,202
24-03-26 2.4 -0.83% 746,179
24-03-25 2.42 -2.42% 1,563,195
24-03-22 2.48 +92.25% 44,376,551

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
IMAC Holdings, Inc. owns and manages health and wellness centers that delivers sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases. The Company provides movement, orthopedic and neurological therapies through its chain of Innovative Medical Advancements and Care (IMAC) Regeneration Centers. The Company, through its outpatient medical clinics, provide conservative, minimally invasive medical treatments to help patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. It operates through two business segments: outpatient medical centers and clinical research division. The Company's research division is conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinson's disease. The Company operates approximately 10 outpatient medical clinics in five states in the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.06 USD
Average target price
10 USD
Spread / Average Target
+226.80%
Consensus
  1. Stock
  2. Equities
  3. Stock IMAC Holdings, Inc. - Nasdaq